Drug Discovery for Ion Channels XVI

Friday, February 26, 2016
8:00AM - 5:15PM
Los Angeles Convention Center
Room 411


PRE-REGISTRATION IS CLOSED.  On-site registration will be accepted.

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. But the advent of automated electrophysiological systems with higher throughput has begun to revolutionize ion channel drug discovery. This symposium focuses on the emerging technology of automated electrophysiology and how it is changing the face of ion channel drug discovery. Speakers from industry and academia will discuss the development and potential of these new technologies, present experimental results obtained using these systems and discuss the impact these technologies are having on ion channel drug discovery.

Agenda

7:30 AM - 8:30 AM Registration / Introduction
Session I, Chair: Niels Fertig
8:30 AM - 9:00 AM

Keynote Speaker: Steve Petrou, Florey Institute, Melbourne, Australia
Wetware in the Loop: Realtime Modelling using Dynamic Clamp for Safety and Drug Discovery

9:00 AM - 9:30 AM

Arturo Picones, Universidad Nacional Autonomia de Mexico, Mexico
Gigaseal Automated Patch-Clamp Recordings of Ion Channel Activity Expressed in Cell Lines and Native Cells

9:30 AM - 10:00 AM 

Matthew Bridgland-Taylor, Astrazeneca, UK
Next Generation Electrophysiology: Comparison of Platforms to Progress Efficacy and Liability Capability at AstraZeneca

10:00 AM - 10:30 AM 

Break 
Session II, Chair: Jeff Webber

10:30 AM - 11:00 AM 

Godfrey Smith, University of Glasgow, Scotland
Optical Methods for Examining Excitation-Contraction Coupling in iPS-Derived Cardiomyocytes and their Application to Medium/High Through-put Assays

11:00 AM - 11:30 AM

David Hackos, Genentech
Identification and Characterization of Novel NMDA Receptor Positive Allosteric Modulators (PAMs)

11:30 AM - 12:00 PM 

Liudmila Polonchuk and Ken Wang, Hoffman La Roche, Switzerland 
Automated Electrophysiology for Translational Cardiac Modelling

12:00 PM - 1:00 PM 

Lunch (provided)
Session III, Chair: Eugenia Jones

1:00 PM - 1:30 PM 

Alison Easter, Biogen
The Combined Use of Ion Channel Studies and Human iPS-Derived Cardiac Myocytes in Preclinical Safety Assessment

1:30 PM -  2:00 PM 

Matthew Fuller, Icagen Inc.
Investigation of Potassium Channel Function Utilizing Human iPSC-Derived Neurons

2:00 PM - 2:30 PM

Rok Cerne, Eli Lilly
Automated Patch Clamp Assays for States Dependent Ion Channel Modulators

2:30 PM - 3:00 PMSophia Lin, Xenon Pharmaceuticals Inc., Canada
Automated Electrophysiology as a Platform for Biophysical Characterization and Ion Channel Drug Discovery
3:00 PM - 3:30 PM B

reak

Session IV, Chair: Richard Kondo

3:30 PM - 4:00 PM 

Roselle Gélinas, Group of Prof John Rioux a MHI (Montreal Heart Institute), Canada
Human iPS Cell-Derived Cardiomyocytes as a Model for Characterization of New LQT Syndrome Mutations

4:00 PM - 4:30 PM 

Alfred George, Magerstadt Professor and Chair, Northwestern University
Coupling High Capacity Electroporation with Automated Patch Clamp Recording for Functional Annotation of Human Ion Channel Variants

4:30 PM - 5:00 PM 

Justin Murray, Amgen
Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3

5:00 PM - 5:15 PM C

losing Remarks, Richard Kondo


Sponsored by: